Tissue-engineered human myobundle system as a platform for evaluation of skeletal muscle injury biomarkers.

Alastair Khodabukus[1#], Amulya Kaza[1#], Jason Wang[1], Neel Prabhu[1], Richard Goldstein[2], Vishal Vaidya[2], and Nenad Bursac[1]

[1] Department of Biomedical Engineering, Duke University, Durham, NC, USA
[2] Drug Research and Development, Pfizer, Groton, CT, USA
#Equally contributing authors
*Corresponding author:
101 Science Drive
FCIEMAS 1427
Durham, NC27708-90281
phone: 1-919-660-5510
fax: 1-919-684-4488
E-mail: nbursac@duke.edu



Supplementary Figure 1. Human myobundle system. (**A**) Human muscle progenitor cells (MPCs) are isolated from muscle biopsies and expanded in culture for 5 passages. Expanded MPCs are embedded at high density in a fibrin/matrigel hydrogel and cast in molds to form pairs of cylindrically shaped tissues (myobundles) anchored to a supporting Cerex® frame. (**B**) Representative myobundle cross-sectional image stained for filamentous-actin (F-actin) and nuclei (DAPI). (**C**) Representative myobundle cross-sectional image at higher magnification showing myofibers stained for dystrophin (Dys). (**D**) Representative whole-myobundle image showing aligned myofibers stained for sarcomeric alpha-actinin (SAA) and nuclei (DAPI).